Abstract: A polarized light source configured for use in display device and backlight unit is described. The polarized light source comprising: at least one optically active structure comprising a plurality of nanorods configured to emit light of one or more wavelengths in response to exciting pumping field, said plurality of nanorods comprising nanorods aligned with a predetermined alignment axis so as to produce a desired polarization direction of the emitted light; and a light directing assembly comprising one or more optical elements in optical path of light emitted from the light emitting structure, said light directing assembly being configured to enhance output of the emitted light from the emitting structure while substantially maintaining the polarization of the emitted light passing therethrough. Preferably, layers associated with the polarized light source are aligned with parallel principal axes.

Abstract: The present invention provides seeded rod (SR) nanostructure systems including an elongated structure embedded with a seed structure being a core/shell structure or a single-material rod element. The SR systems disclosed herein are suitable for use in a variety of electronic and optical devices.

Abstract: The invention provides articles and methods for making such articles including a substrate coated on at least one region thereof with a layer of nanocomposites nano-cellulose materials and nanoparticles.

Abstract: Provided is a process and system for the production of a nutritional low-caloric food product, and food products produced thereby.

Abstract: Provided is a natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.

Abstract: The present invention provides a bio-fuel, wood or other product, such as a paper, textile or yarn product. The product can contain material from a transgenic plant over-expressing a nucleic acid molecule encoding an enzyme that causes the plant cell wall to be more water soluble than the wild type.

Abstract: The present invention relates to the field of cancer treatment, particularly to a novel constructs useful for treating tumors expressing H19 and/or IGF-II. More specifically, the invention provides compositions and methods utilizing a nucleic acid construct enabling expression of a cytotoxic gene product directed by more than one tumor specific promoter.

Abstract: Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.

Abstract: Provided herein are pre-lyophilized compositions containing a nucleic acid, a cationic polymer, and a carbohydrate. Also provided are lyophilized compositions of matter and reconstituted compositions as well as methods of making using the same for treating tumors in patients.

Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.

Abstract: Provided are oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, compositions including said oligonucleotides, kits including the compositions, and uses thereof. In particular, the subject matter provides compositions of oligonucleotides useful in methods for suppressing exon skipping optionally in combination with additional CFTR therapeutics.

Abstract: The invention relates to a process for generating hydrogen, comprising decomposing in a reaction vessel aqueous alkali formate in the presence of a transition metal-containing catalyst system dissolved in one or more organic solvent(s), characterized in that said organic solvent(s) comprise at least one solvent which is water-immiscible, thereby releasing hydrogen and forming bicarbonate in the aqueous phase, and separating the catalyst-containing organic solvent(s) from said bicarbonate. Also disclosed are apparatuses for carrying out hydrogen generation.

Abstract: The present invention provides seeded rod (SR) nanostructure systems including an elongated structure embedded with a seed structure being a core/shell structure or a single-material rod element. The SR systems disclosed herein are suitable for use in a variety of electronic and optical devices.

Abstract: The present invention relates to novel plants, in particular to pepper plants capable of producing fruits which can be kept a longer period of time on the plant as well as being stored after harvesting under refrigerated conditions without exhibiting excessive softening.

Abstract: Cyclic nitroxide compounds including, but not limited to, compounds having the general formula I: wherein the dashed line and R1-R8 are as defined herein, are disclosed herein for use in treating diseases and disorders of the respiratory tract and/or respiratory tract remodeling.

Abstract: Provided is a self-processing synthesis of hybrid nanostructures, novel nanostructures and uses thereof in the construction of electronic and optoelectronic devices.

Abstract: Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.

Abstract: Synthetic peptides containing chemical modifications having anti-tumor properties are provided. Further provided are pharmaceutical compositions including the peptides and use thereof for treating proliferative and neoplastic diseases such as cancer.

Abstract: Compositions and methods for treating diseases or disorders associated with the metabolic syndrome using conjugates of bile acids with basic amino acids or a decarboxylated amino acid such as agmatine are provided. Further provided are bile acid-basic amino acid conjugates including chenodeoxycholic acid with an amino acid selected from arginine, lysine, histidine, ornithine or a decarboxylated amino acid such as agmatine.

Abstract: Provided are compositions and methods of targeting imaging or therapeutic agents to cancer sites using Fap2. Also provided are methods of treating cancer by inhibiting the complexing of Fusobacterium nucleatum Fap2 and Gal-GalNAc molecules expressed on cancer cells.